## Exhibit P

## MAZIE SLATER KATZ & FREEMAN, LLC

103 Eisenhower Parkway, Suite 207, Roseland, NJ 07068 Phone: (973) 228-9898 - Fax: (973) 228-0303

www.mazieslater.com

David A. Mazie\* Adam M. Slater\*° Eric D. Katz\*° David M. Freeman Beth G. Baldinger Matthew R. Mendelsohn° David M. Estes Writer's Direct Dial & Email: (973) 228-0454 aslater@mazieslater.com

Karen G. Kelsen° Cheryll A. Calderon Adam M. Epstein° Cory J. Rothbort\*° Michael R. Griffith° Christopher J. Geddis Alexander Q. Reynoso Samuel G. Wildman Julia S. Slater°

\*Certified by the Supreme Court of New Jersey as a Civil Trial Attorney

°Member of N.J. & N.Y. Bars

November 18, 2020

## VIA EMAIL

Jessica Priselac, Esq. Duane Morris 505 9th Street, N.W., Suite 1000 Washington, DC 20004-2166

Re: In re Valsartan, Losartan, and Irbesartan Products Liability Litigation, No. 1:19-md-02875

## Counsel:

Pursuant to paragraph 20 of the Confidentiality and Protective Order entered in this matter, plaintiffs hereby object to the following confidentiality designations:

- 1. ZHP00406066 ZHP00406069 Email communication between ZHP employees regarding the response to the FDA's Warning Letter
- 2. PRINSTON00073431 PRINSTON00073442 Communication between the FDA and ZHP attaching the Form FDA 483, Inspectional Observations.
- 3. PRINSTON00156783 PRINSTON00156805 Research and Development Report of Valsartan
- 4. PRINSTON00147188 PRINSTON00147188 FDA Warning Letter
- 5. PRINSTON00077339 PRINSTON00077344 FDA Warning Letter

6. PRINSTON0000142398 – PRINSTON00142403 – Printout of Warning Letter from FDA Website

7. PRINSTON00159844 - PRINSTON00159898 - Complaint and Jury Demand

As shown by their respective descriptions, the above documents do not contain any proprietary, trade secret, or highly sensitive commercial information and certainly do not meet the standard for "CONFIDENTIAL INFORMATION" as defined in paragraph 9(B) of the Confidentiality and Protective Order. In addition, these documents relate to matters of public health and safety, and are either already available in the public sphere or presumptively to be public and non-confidential. As such, plaintiffs request ZHP de-designate these documents or promptly meet and confer regarding any refusal to do so.

Very Truly Yours,

ADAM M. SLATER

cc: Joseph S. Ferretti, Esq Seth A. Goldberg, Esq.